This is the authors' abstract. We don't add key points for this paper.
Epstein-Barr virus (EBV) is associated with a range of epithelial and B cell malignancies as well as autoimmune disorders, for which there are still no specific treatments or effective vaccines. Here, we isolated EBV gH/gL-specific antibodies from an EBV-infected individual. One antibody, 1D8, efficiently neutralized EBV infection of two major target cell types, B cells and epithelial cells. In humanized mice, 1D8 provided strong protection against a high-dose EBV challenge by substantially reducing viral loads and associated tumor burden. Crystal structure analysis revealed that 1D8 binds to a key vulnerable interface between the D-I/D-II domains of the viral gH/gL protein, especially the D-II of the gH, thereby interfering with the gH/gL-mediated membrane fusion and binding to target cells. Overall, we identified a potent neutralizing antibody as a promising candidate for prophylactic and therapeutic interventions against EBV infection. The key vulnerable site also provides insights into the EBV vaccines design.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: